Seek Returns logo

UHS vs. VTRS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at UHS and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolUHSVTRS
Company NameUniversal Health Services, Inc.Viatris Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Providers & ServicesPharmaceuticals
Market Capitalization11.70 billion USD12.30 billion USD
ExchangeNYSENasdaqGS
Listing DateJuly 9, 1981March 17, 1980
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of UHS and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

UHS vs. VTRS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolUHSVTRS
5-Day Price Return0.72%-1.22%
13-Week Price Return-1.48%24.12%
26-Week Price Return0.25%-3.48%
52-Week Price Return-19.80%-9.83%
Month-to-Date Return10.47%20.71%
Year-to-Date Return2.49%-15.26%
10-Day Avg. Volume0.70M8.78M
3-Month Avg. Volume0.89M12.06M
3-Month Volatility31.24%31.14%
Beta1.300.91

Profitability

Return on Equity (TTM)

UHS

18.62%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

In the upper quartile for the Health Care Providers & Services industry, UHS’s Return on Equity of 18.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

VTRS

-19.92%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

UHS vs. VTRS: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

UHS

7.66%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

A Net Profit Margin of 7.66% places UHS in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.

VTRS

-24.57%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

UHS vs. VTRS: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

UHS

10.99%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

An Operating Profit Margin of 10.99% places UHS in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

VTRS

-26.54%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

UHS vs. VTRS: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolUHSVTRS
Return on Equity (TTM)18.62%-19.92%
Return on Assets (TTM)8.60%-8.50%
Net Profit Margin (TTM)7.66%-24.57%
Operating Profit Margin (TTM)10.99%-26.54%
Gross Profit Margin (TTM)--40.15%

Financial Strength

Current Ratio (MRQ)

UHS

1.29

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

UHS’s Current Ratio of 1.29 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.

VTRS

1.37

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

UHS vs. VTRS: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

UHS

0.65

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

UHS’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

VTRS

0.82

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

UHS vs. VTRS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

UHS

9.05

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

UHS’s Interest Coverage Ratio of 9.05 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

VTRS

-0.13

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

UHS vs. VTRS: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolUHSVTRS
Current Ratio (MRQ)1.291.37
Quick Ratio (MRQ)1.190.65
Debt-to-Equity Ratio (MRQ)0.650.82
Interest Coverage Ratio (TTM)9.05-0.13

Growth

Revenue Growth

UHS vs. VTRS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

UHS vs. VTRS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

UHS

0.45%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

UHS’s Dividend Yield of 0.45% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

VTRS

4.58%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

UHS vs. VTRS: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

UHS

4.19%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

UHS’s Dividend Payout Ratio of 4.19% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

VTRS

137.04%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

UHS vs. VTRS: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolUHSVTRS
Dividend Yield (TTM)0.45%4.58%
Dividend Payout Ratio (TTM)4.19%137.04%

Valuation

Price-to-Earnings Ratio (TTM)

UHS

9.33

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

In the lower quartile for the Health Care Providers & Services industry, UHS’s P/E Ratio of 9.33 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

VTRS

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for VTRS is currently unavailable.

UHS vs. VTRS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

UHS

0.71

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

UHS’s P/S Ratio of 0.71 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

VTRS

0.88

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

UHS vs. VTRS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

UHS

1.66

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

UHS’s P/B Ratio of 1.66 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

VTRS

0.67

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

UHS vs. VTRS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolUHSVTRS
Price-to-Earnings Ratio (TTM)9.33--
Price-to-Sales Ratio (TTM)0.710.88
Price-to-Book Ratio (MRQ)1.660.67
Price-to-Free Cash Flow Ratio (TTM)13.057.29